Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

Journal of Clinical Investigation

Volumn 113, Issue 5, 2004, Pages 709-717

  Quaglino, Elena ^a   Rolla, Simona ^a   Iezzi, Manuela ^b   Spadaro, Michela ^a   Musiani, Piero ^b   De Giovanni, Carla ^c   Lollini, Pier Luigi ^c   Lanzardo, Stefania ^a   Forni, Guido ^a,d   Sanges, Remo ^e   Crispi, Stefania ^e   De Luca, Pasquale ^e   Calogero, Raffaele ^a   Cavallo, Federica ^a,f  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CERMS   (Italy)

^e INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^f SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; PROTEIN P185; VACCINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; FEMALE; GENE EXPRESSION; HYPERPLASIA; MAMMARY GLAND; MOUSE; NONHUMAN; ONCOGENE NEU; PLASMID; PRECANCER; PRIORITY JOURNAL; TUMOR GROWTH; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MEMBRANE; CLUSTER ANALYSIS; CONFOCAL MICROSCOPY; DNA MICROARRAY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; NEOPLASM; PROTEIN TERTIARY STRUCTURE; RAT; TIME; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CELL MEMBRANE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMIDS; PRECANCEROUS CONDITIONS; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 85047694236     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19850     Document Type: Article

References (48)

1. Forni, G., Lollini, P.L., Musiani, P., and Colombo, M.P. 2000. Immunoprevention of cancer: is the time ripe? Cancer Res. 60:2571-2575.
2. Lollini, P.-L., and Forni, G. 2003, Cancer immunoprevention: tracking down persistent tumor antigen. Trends Immunol. 24:62-66.
3. Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:105-115.
4. Lucchini, F., et al. 1992. Early and multifocal tumors in breasr, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett. 64:203-209.
5. Boggio, K., et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188:589-596.
6. Di Carlo, E., et al. 1999. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 79:1261-1269.
7. Rovero, S., et al. 2000. DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165:5133-5142.
8. Cappello, P., et al. 2003. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63:2518-2525.
9. Cavallo, F., et al. 2001. IL12-activated lymphocytes influence tumor genetic programs. Cancer Res. 61:3518-3523.
10. Di Carlo, E., et al. 2001. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin. Cancer Res. 7:830-837.
11. Rovero, S., et al. 2001. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther. 8:447-452.
12. Ramshaw, I.A., and Ramsay, A.J. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today. 21:163-165.
13. McShane, H. 2002. Prime-boost immunization strategies for infectious diseases. Curr. Opin. Mol. Ther. 4:23-27.
14. Robinson, H.L. 2003. Prime boost vaccines power up in people. Nat. Med. 9:642-43.
15. Nanni, P., et al. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194:1195-1205.
16. Lollini, P.L., et al. 1993. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer. 55:320-329.
17. Qin, Z., et al. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627-630.
18. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187-376.
19. Irizarry, R.A., et al. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e15.
20. Li, C., and Wong, W.H. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci U. S. A. 98:31-36.
21. Saviozzi, S., Iazzetti, G., Caserta, E., Guffanti, A., and Calogero, R.A. 2003. Microarray data analysis and mining. In Methods in molecular medicine: molecular diagnosis of infectious diseases. J. Decker and U. Reischl, editors. Humana Press Inc. Totowa, Massachusetts. 67-90.
22. Tusher, V.G., Tibshirani, R., and Chu, G. 2001. Significance analysis of microarrays applied to the ionising radiation response. Proc. Natl. Acad. Sci. U. S. A. 98:5116-5121.
23. Quaglino, E., et al. Concordant morphologic and gene expression data show that a vaccine freezes HER-2/neu preneoplastic lesions (additional information page). http://www.bioinformatica.unito.it/bioinformatics/Forni/additional_info/.
24. Raychaudhuri, S., Stuart, J.M., and Altman, R.B. 2000. Principal components analysis to summarize microarray experiments: application to sporulation time series. In Pacific Symposium on Biocomputing 2000. World Scientific. Singapore; River Edige, New Jersey, USA. 452-463. SMI Report No. SMI-1999-0804.
25. Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868.
26. Ashbumer, M., et al. 2001. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25:25-29.
27. Kaminski, N., and Friedman, N. 2002. Practical approaches to analysing results of microarray experiments. Am. J. Respir. Cell. Mol. Biol. 27:125-132.
28. Basilevsky, A. 1994. Statistical factor analysis and related methods. John Wiley & Sons. New York, New York, USA.
29. Everitt, B.S., and Dunn, G. 1992. Applied multivariate data analysis. Oxford University Press. New York, New York, USA.
30. Pearson, K. 1901. On lines and planes of closest fit to systems of points in space. The London, Edinburgh and Dublin Philosophical Magazine and Journal of Science. 2:559-572.
31. Nakamura, A., et al. 2003. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J. Exp. Med. 197:669-674.
32. Bolin, L.M., et al. 1997. HNMP-I: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury. J. Neurosci. 17:5493-5502.
33. Stoica, G.E., et al. 2002. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277:35990-35998.
34. Okumura, M., Kung, C., Wong, S., Rodgers, M., and Thomas, M.L. 1998. Definition of family of coronin-related proteins conserved between humans and mice: close genetic linkage between coronin-2 and CD45-associated protein. DNA Cell Biol. 17:779-787.
35. Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R.P., and Samelson, L.E. 1998. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 92:83-92.
36. Klapper, L.N., et al. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER-2 blocks crosstalk with growth factor receptors. Oncogene. 14:2099-2109.
37. Katsumata, M., et al. 1995. Prevention of breast tumor development in vivo by downregulation of the p 185(neu) receptor. Nat. Med. 1:644-648.
38. Yip, Y.L., and Ward, R.L. 2002. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol. Immunother. 50:569-587.
39. Klapper, L.N., Waterman, H., Sela, M., and Yarden, Y. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cb1 and enhancing ubiquitination of HER-2. Cancer Res. 60:3384-3388.
40. Hunter, T. 2000. Signaling - 2000 and beyond. Cell. 100:113-127.
41. Oved, S., and Yarden, Y. 2002. Molecular tickets to enter cells. Nature. 416:133-136.
42. Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mechanism of action of trascuzumab (Herceptin). Semin. Oncol. 26:60-70.
43. Herr, A.B., Ballister, E.R., and Bjorkman, P.J. 2003. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature. 423:614-620.
44. Musiani, P., et al. 1997. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today 18:32-36.
45. Lollini, P.L., et al. 1995. Systemic effects of cytokines released by gene-transduced tumor cells: marked hyperplasia induced in small bowel by gamma-interferon transfectants through host lymphocytes. Int. J. Cancer. 61:425-430.
46. Sauter, B., et al. 2000. Consequences of cell death: exposure to necrotic tumor cells, bur nor primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:423-434.
47. Gullick, W.J. 2002. A new model for ductal carcinoma in situ suggests strategies for treatment. Breast Cancer Res. 4:176-178.
48. Van't Veer, L.J., and De Jong, D. 2002. The microarray way to tailored cancer treatment. Nat. Med. 8:13-14.